Rijswijk, NETHERLANDS, March 17, 2017 /PRNewswire/ -- DSM Sinochem Pharmaceuticals (DSP) and Sandoz (a Novartis Division)announced today that they have executed a definitive agreement licensing certain DSP intellectual property assets for the manufacture of beta lactam antibiotics.
The license agreement provides Sandoz a non-exclusive, worldwide license to certain
Karl Rotthier, CEO of DSP stated: "DSP is pleased to have Sandoz as a licensee of our innovative, sustainable and environmentally friendly amoxicillin manufacturing technology. As part of our commitment to fight antimicrobial resistance through minimizing the environmental impact from antibiotics manufacturing, DSP is actively seeking to promote green, enzymatic routes for production of amoxicillin and other antibiotics, utilizing our patented technology. This license agreement further validates the strength of DSP's intellectual property portfolio regarding enzymatically produced antimicrobials."
The commitment to reduce environmental impact from the production of antibiotics is also laid out in the Industry Roadmap for Progress on Combating Antimicrobial Resistance, signed by DSP, Novartis and 11 other leading pharmaceutical companies at the United Nations General Assembly in New York in September 2016.
About DSM Sinochem PharmaceuticalsDSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.
Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.
Please visit www.dsm-sinochem.com for more information or contactDSM Sinochem Pharmaceuticals Corporate CommunicationsAlice Beijersbergen, Head of Corporate CommunicationsE-Mail: firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dsm-sinochem-pharmaceuticals-announces-licensing-agreement-for-intellectual-property-assets-related-to-the-manufacture-of-beta-lactam-antibiotics-300425551.html
SOURCE DSM Sinochem Pharmaceuticals
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All